Chapter title |
Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer
|
---|---|
Chapter number | 23 |
Book title |
Urothelial Carcinoma
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7234-0_23 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7233-3, 978-1-4939-7234-0
|
Authors |
Anuja Sathe, Roman Nawroth, Sathe, Anuja, Nawroth, Roman |
Abstract |
The PI3K/AKT/mTOR signaling pathway shows frequent molecular alterations and increased activity in cancer. Given its role in the regulation of cell growth, survival and metastasis, molecules within this pathway are promising targets for pharmacologic intervention. Metastatic bladder cancer (BLCA) continues to have few treatment options. Although various molecular alterations in PI3K/AKT/mTOR signaling have been described in BLCA, clinical trials with small molecule inhibitors have not met their endpoints. In this article, we summarize results from preclinical studies and clinical trials that examined PI3K pathway inhibitors in BLCA focusing on technical challenges that might result in contradictory findings in preclinical studies. Based on published data from our group, we also address challenges that need to be overcome to optimize PI3K inhibition in BLCA and enable its successful translation into the clinic. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 30 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 23% |
Student > Ph. D. Student | 4 | 13% |
Student > Doctoral Student | 3 | 10% |
Student > Master | 2 | 7% |
Student > Postgraduate | 2 | 7% |
Other | 4 | 13% |
Unknown | 8 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 6 | 20% |
Medicine and Dentistry | 4 | 13% |
Agricultural and Biological Sciences | 3 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Immunology and Microbiology | 1 | 3% |
Other | 3 | 10% |
Unknown | 12 | 40% |